RekrutujeFaza II
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Miasta: Bydgoszcz, Gdańsk, Katowice, Kraków i 6 innych miastWiek: od 18 latSponsor: Urogen Pharma Ltd.
RekrutujeFaza III
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Miasta: Gdańsk, Lublin, Poznań, Skórzewo i 2 inne miastaWiek: od 18 latSponsor: Summit Therapeutics Inc.
RekrutujeFaza III
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels…
Miasta: Gdańsk, Gliwice, Lublin, Poznań i 2 inne miastaWiek: od 18 latSponsor: Pfizer Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic…
Miasta: Białystok, Kraków, Lublin, Poznań i 2 inne miastaWiek: od 18 latSponsor: Immunitybio Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Miasta: Bielsko-Biala, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Daiichi Sankyo Inc.
RekrutujeFaza II/III
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Miasta: Białystok, Bydgoszcz, Gdańsk, Gliwice i 11 innych miastWiek: od 18 latSponsor: BioNTech SE
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Miasta: Białystok, Gdańsk, Katowice, Konin i 9 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Miasta: Biała Podlaska, Białystok, Bydgoszcz, Bystra i 6 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza II/III
Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care…
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 11 innych miastWiek: do 17.99 latSponsor: Medical University Of Lodz
RekrutujeFaza III
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 9 innych miastWiek: do 64 latSponsor: Medical University Of Gdansk
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy…
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 11 innych miastWiek: do 64 latSponsor: Universita Degli Studi Di Milano Bicocca
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume…
Miasta: Gliwice, PoznańWiek: od 18 latSponsor: Centre Leon Berard
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab…
Miasta: Bydgoszcz, Konin, Poznań, Prabuty i 2 inne miastaWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Miasta: Biała Podlaska, Białystok, Bydgoszcz, Bystra i 6 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Miasta: Gdańsk, Kielce, Kraków, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Miasta: Białystok, Gdańsk, Kraków, Poznań i 4 inne miastaWiek: od 18 latSponsor: Genmab A/S
W Polsce: ZakończoneNa świecie: RekrutujeFaza I/II
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer
Miasta: Gdańsk, Otwock, Poznań, WarszawaWiek: od 18 latSponsor: Fortvita Biologics (USA) Inc.
RekrutujeFaza III
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer…
Miasta: Bydgoszcz, Konin, Koszalin, Poznań i 3 inne miastaWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle…
Miasta: Bydgoszcz, Poznań, WarszawaWiek: od 18 latSponsor: Ferring Pharmaceuticals
RekrutujeFaza III
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Miasta: Bydgoszcz, Poznań, WarszawaWiek: od 18 latSponsor: Ferring Pharmaceuticals
RekrutujeFaza III
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Miasta: Katowice, Olsztyn, Poznań, Wrocław i 1 inne miastoWiek: od 18 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza III
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 12 innych miastWiek: od 18 latSponsor: Kartos Therapeutics Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with…
Miasta: Gdańsk, Poznań, WrocławWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Miasta: Bydgoszcz, Gdańsk, Konin, Lublin i 2 inne miastaWiek: od 18 latSponsor: OSE Immunotherapeutics
RekrutujeFaza I
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Miasta: Gdańsk, Kraków, Poznań, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Duke Street Bio Limited
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC)…
Miasta: Białystok, Kielce, Otwock, Poznań i 3 inne miastaWiek: od 18 latSponsor: Bayer AG
RekrutujeFaza III
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With…
Miasta: Biała Podlaska, Białystok, Kraków, Poznań i 1 inne miastoWiek: od 18 latSponsor: Jazz Pharmaceuticals Ireland Limited
RekrutujeFaza III
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Miasta: Białystok, Bydgoszcz, Gorlice, Grudziądz i 7 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC